121 Aufrufe 121 0 Kommentare 0 Kommentare

Taglich Brothers Publishes Updated Coverage Report on Cosmos Health; Maintains Price Target of $4, Nearly 300% Above Current Share Price

CHICAGO, IL / ACCESSWIRE / September 17, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and …

CHICAGO, IL / ACCESSWIRE / September 17, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that on September 16, 2024, Taglich Brothers, Inc. ("Taglich Brothers") published its updated research report on the Company's common stock.

Key highlights of Taglich Brothers' updated coverage report include:

Anzeige 
Handeln Sie Ihre Einschätzung zu Nasdaq Stock Market Inc!
Short
84,49€
Basispreis
0,55
Ask
× 13,41
Hebel
Zum Produkt
Long
73,31€
Basispreis
0,66
Ask
× 11,76
Hebel
Zum Produkt
Präsentiert von

Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

  • Maintains Speculative Buy rating with a $4 price target, implying a nearly four-fold share price increase over the next 12 months.

  • Significant growth is expected as the Company transitions into a vertically integrated global health organization, driven by increased contract manufacturing at Cana Laboratories and expanded distribution agreements for its nutraceutical and disinfectant brands in Europe and the Middle East.

  • FY 2024 revenue is forecasted at $56.3 million, with a 22.6% increase to $69.0 million in FY 2025, alongside a projected operating profit of $20,000 and cash earnings of $1.6 million.

  • Valuation should improve with revenue growth, transitioning to operating profit and positive cash earnings, as Cosmos Health's price-to-sales multiple (0.3X) lags behind the 2.4X sector average for similar companies in medical distribution and drug manufacturing.

  • Investors are likely to assign a valuation multiple closer to industry standards. Applying a 1.4X price-to-sales multiple to the 2025 sales per share forecast of $3.86 supports the $4 price target, factoring in execution risks and potential warrant dilution.

Greg Siokas, CEO of Cosmos Health, stated: "I am pleased that Taglich Brothers has reaffirmed its price target of $4-nearly four times our current share price. Taglich highlights strong growth potential driven by, among other factors, our strategic investments in Cana, including new contract manufacturing agreements, and the expansion of our proprietary brands globally. In fact, Taglich expects Cosmos to be cash flow positive in 2025. As I've consistently emphasized, I believe our stock remains undervalued given our achievements and growth outlook, and I'm encouraged to see that Taglich shares this view."

Seite 1 von 3


Diskutieren Sie über die enthaltenen Werte



Accesswire
0 Follower
Autor folgen
Mehr anzeigen
We’re a newswire service standout and fast becoming an industry disruptor. We provide regional, national and global news to thousands of clients around the world. We’re also leading the way in social engagement, targeting and analytics.
Mehr anzeigen

Verfasst von Accesswire
Taglich Brothers Publishes Updated Coverage Report on Cosmos Health; Maintains Price Target of $4, Nearly 300% Above Current Share Price CHICAGO, IL / ACCESSWIRE / September 17, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and …

Wenn Sie Kursdaten, Widgets oder andere Finanzinformationen benötigen, hilft Ihnen ARIVA gerne. 

Unsere User schätzen wallstreet-online.de: 4.8 von 5 Sternen ermittelt aus 285 Bewertungen bei www.kagels-trading.de
Zeitverzögerung der Kursdaten: Deutsche Börsen +15 Min. NASDAQ +15 Min. NYSE +20 Min. AMEX +20 Min. Dow Jones +15 Min. Alle Angaben ohne Gewähr.
Werbehinweise:
Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.
Copyright © 1998-2025 Smartbroker Holding AG - Alle Rechte vorbehalten. Mit Unterstützung von: Ariva Smartbroker+ Daten & Kurse von TTMzero